The Technical Analyst
Sigyn Therapeutics, Inc. [SIGY]
Exchange: OTC Sector: Healthcare Industry: Biotechnology
Sigyn Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $5.25
America/New_York / 3 mai 2024 @ 13:41
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6.76 mill |
| EPS: | -3.60 |
| P/E: | -1.460 |
| Earnings Date: | May 16, 2023 |
| SharesOutstanding: | 1.288 mill |
| Avg Daily Volume: | 0.0001 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.460 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -1.460 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.91 - 5.59 ( +/- 6.55%) |
| ATR Model: 14 days |
Forecast:
15:21 - $5.13
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $5.25 (0.00% ) |
| Volume | 0.0003 mill |
| Avg. Vol. | 0.0001 mill |
| % of Avg. Vol | 283.02 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SIGY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SIGY
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.
Latest Press Releases
2024-03-05 09:00:00 - Press Release
Sigyn Therapeutics™ To Present At Tomorrow's Emerging Growth Conference
Live online presentation scheduled at 12 pm est on march 6 th san diego, ca, march 05, 2024 (globe newswire) -- via newmediawire -- sigyn therapeutics, inc. (“sigyn therapeutics” or the “company”) (otcqb:”sigy”), a development-stage medical technology company, announced today that its ceo, jim joyce will give a live presentation at tomorrow's emerging growth conference. the presentation is scheduled to begin at 12 pm eastern standard time.
2024-02-21 08:45:00 - Press Release
Sigyn Therapeutics™ Announces Filing Of 2023 Annual Report On Sec Form 10-k
San diego, ca, feb. 21, 2024 (globe newswire) -- via newmediawire – sigyn therapeutics, inc. (“sigyn therapeutics” or the “company”) (otcqb: “sigyd” – “sigy”), a development-stage medical technology company, announced today the filing of its form 10-k annual report with the united states securities and exchange commission ("sec") for the year-ended december 31, 2023.
2024-02-01 18:25:00 - Press Release
Sigyn Therapeutics Completes Reverse Stock Split
San diego, ca, feb. 01, 2024 (globe newswire) -- via newmediawire –sigyn therapeutics, inc. (“sigyn” or the “company”) (otcqb: “sigyd”, “sigy”), a development-stage medical technology company, disclosed today that a 1-for-40 reverse split of its common stock was implemented on january 31, 2024. as a result of the split, the company's common stock will trade under the ticker symbol “sigyd” for 20 business days and subsequently revert to trading under its historic symbol “sigy” on february 29, 2024.
2024-01-30 08:45:00 - Press Release
Sigyn Therapeutics Announces Reverse Stock Split
San diego, ca, jan. 30, 2024 (globe newswire) -- via newmediawire -- sigyn therapeutics, inc. (“sigyn” or the “company”) (otcqb: sigy), a development-stage medical technology company, today announced that a 1-for-40 reverse split of its common stock will be implemented tomorrow, january 31, 2024. as a result, the company's common stock will trade on a post-split basis at the beginning of the trading day on january 31st under its existing trading symbol “sigy.” the cusip number for the common stock following the reverse stock split will be 82674u205.
2023-12-12 08:30:00 - Press Release
Sigyn Therapeutics Announces Appointment Of Jerry Deciccio As Chief Financial Officer
San diego, ca, dec. 12, 2023 (globe newswire) -- via newmediawire -- sigyn therapeutics, inc. (“sigyn” or the “company”) (otcqb: sigy), a development-stage medical technology company, today announced the appointment of jerry deciccio, cpa, mba, as chief financial officer.
Latest News
2024-03-05 09:00:00 - GlobeNewsWire
Sigyn Therapeutics™ to Present at Tomorrow's Emerging Growth Conference
Live Online Presentation Scheduled at 12 pm EST on March 6 th SAN DIEGO, CA, March 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OTCQB:”SIGY”), a development-stage medical technology company, announced today that its CEO, Jim Joyce will give a live presentation at tomorrow's Emerging Growth Conference. The presentation is scheduled to begin at 12 pm eastern standard time.
2023-08-08 10:30:00 - GlobeNewsWire
Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference
SAN DIEGO, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB:SIGY), a medical technology company that creates blood purification devices to overcome clearly defined limitations in healthcare, announced today that Jim Joyce, its Chairman and CEO, will present at tomorrow's Emerging Growth Conference.
2022-01-25 08:00:00 - GlobeNewsWire
Sigyn Therapeutics to Present at the Bullseye Small Cap Virtual Investor Conference
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-related conditions that precipitate sepsis, announced that its Chairman and CEO, Jim Joyce, will give a corporate presentation at the upcoming Bullseye Small Cap Virtual Investor Conference to be held on January 27th and 28th, 2022.
2021-08-30 07:30:00 - GlobeNewsWire
Sigyn Therapeutics Featured on National Public Radio: “Addressing the Cytokine Storm”
SAN DIEGO, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by cytokine storm syndrome, announced today that Tech Nation has conducted an interview with Sigyn Co-founder and CEO, Jim Joyce. Founded in 1993, Tech Nation is a weekly National Public Radio program hosted by Dr. Moira Gunn.
2021-08-23 19:29:00 - Newsfile Corp
Sigyn Therapeutics, Inc. Announces Participation in the Q3 Virtual Investor Summit
San Diego, California--(Newsfile Corp. - August 23, 2021) - Sigyn Therapeutics, Inc. (OTC Pink: SIGY) today announced that Jim Joyce, Chairman & CEO will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 17th at 4:15 PM ET
2021-08-17 12:02:00 - Newsfile Corp
Sigyn Therapeutics, Inc. Announces Participation in the Q3 Virtual Investor Summit
San Diego, California--(Newsfile Corp. - August 17, 2021) - Sigyn Therapeutics, Inc. (OTC Pink: SIGY) today announced that Jim Joyce, Chairman & CEO will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation
2021-08-16 09:00:00 - Newsfile Corp
Sigyn Therapeutics, Inc. Announces Participation in the Q3 Virtual Investor Summit
San Diego, California--(Newsfile Corp. - August 16, 2021) - Sigyn Therapeutics, Inc. (OTC Pink: SIGY) today announced that Jim Joyce, Chairman & CEO will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 17th at 4:15 PM ET
2021-08-10 06:30:00 - GlobeNewsWire
Sigyn Therapeutics CEO Note: A Treatment Candidate to Address Bloodstream Pathogens, Deadly Toxins and Inflammatory Disease Targets
SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of sepsis and other life-threatening inflammatory conditions, today released the following note authored by its Chairman and CEO, Jim Joyce.
2021-07-29 10:06:00 - GlobeNewsWire
Sigyn Therapeutics Announces Successful Completion of Animal Pilot Study
SAN DIEGO, CA, July 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions, today announced the completion of a pilot animal study that validated the feasibility of a clinical protocol that resulted in the safe administration of Sigyn Therapy™ during six-hour treatment exposures. The pilot study represents the first-in-mammal use of Sigyn Therapy in a clinical setting.
2021-01-25 08:00:00 - Newsfile Corp
Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. Discusses Treatment of Life-Threatening Conditions Induced by Cytokine Storm Syndrome
Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - January 25, 2021) - Investorideas.com, a global news source and leading retail investor and trader resource issues a new CEO interview for the Podcast Corner. In today's special edition, Investor Ideas talks to Sigyn Therapeutics, Inc. (OTC Pink: SIGY) Chairman and CEO, Jim Joyce.Previously, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, Inc. Listen to today's Podcast: https://www.investorideas.com/Audio/Podcasts/2021/012021SIGY-CEO-Interview.mp3.Listen to...